Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?

Metabolomics changes in COVID-19 predict acute patient outcomes and suggest a role for a bioenergetic crisis. Thus, metabolomics changes in COVID-19 may serve as a biomarker and provide insight into pathogenic mechanisms and pharmacologic targets. https://bit.ly/2XkJeU8

Detalles Bibliográficos
Autores principales: Hartsell, Emily M., Gillespie, Mark N., Langley, Raymond J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542864/
https://www.ncbi.nlm.nih.gov/pubmed/34675049
http://dx.doi.org/10.1183/13993003.02417-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542864/
https://www.ncbi.nlm.nih.gov/pubmed/34675049
http://dx.doi.org/10.1183/13993003.02417-2021

Ejemplares similares